中国医学前沿杂志（电子版）2026，Vol.18Issue(3)：1-11,11.DOI:10.12037/YXQY.2026.03-01
2025年ESGO-ESTRO-ESP子宫内膜癌患者管理指南解读
Interpretation of the 2025 ESGO-ESTRO-ESP guidelines for the management of patients with endometrial cancer
摘要
Abstract
In 2023,based on advances in understanding the pathological and molecular characteristics of endometrial cancer,The International Federation of Gynaecology and Obstetrics(FIGO)released an updated staging system for endometrial cancer.This system aims to more accurately stratify prognostic groups and identify relevant treatment subgroups by incorporating factors reflecting tumor biological characteristics(histological subtype,lymphovascular space invasion,and molecular classification)and refining anatomical factors(peritoneal metastatic carcinoma and lymph node metastasis).To improve the quality of diagnosis and treatment for patients with gynecological cancers,in 2025,the European Society of Gynaecological Oncology(ESGO),the European Society for Radiotherapy and Oncology(ESTRO),and the European Society of Pathology(ESP)updated the evidence-based ESGO-ESTRO-ESP guidelines originally published in 2021.This updated version incorporates the revised FIGO staging criteria and includes a large body of new evidence on the management of endometrial cancer.This article interprets the new guidelines to facilitate their application in the diagnosis and treatment of endometrial cancer.关键词
子宫内膜癌/分子分型/指南解读Key words
Endometrial cancer/Molecular classification/Guideline interpretation引用本文复制引用
赵小玲,蔡昱..2025年ESGO-ESTRO-ESP子宫内膜癌患者管理指南解读[J].中国医学前沿杂志（电子版）,2026,18(3):1-11,11.基金项目
Capital Health Research and Development of Special Fund(2024-1-2112) 首都卫生发展科研专项(首发2024-1-2112) （2024-1-2112）
